Pascal F Gelebart

Keywords immunotherapy CAR T cells glycosylation sialyl-Tn cancer antibodies glycobiology solid tumors Introduction Chimeric antigen receptor (CAR) T cell therapy has garnered significant attention for its remarkable clinical success in the treatment of hematological malignancies.1,2,3 However, the successful translation of CAR T cell immunotherapy to treat solid tumors remains a difficult task.4,5,6,7 Aside from the challenging accessibility of certain anatomical regions and the presence of...

Highlights • CD37 is expressed on AML blasts • CD37 expression correlates with ELN 2017 risk stratification • CD37CAR T cells are efficient against AML in vitro and in vivo • CD37CAR T cells do not deplete myeloid progenitors Summary Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed.

Materials and methods RNA-Seq data from The Cancer Genome Atlas (TCGA, released July 27, 2022) project for OC for 378 tumor samples was used. The analysis was performed in R (https://www.r-project.org/ (accessed in 2022)) using Bioconductor (https://www.bioconductor.org) packages. The corresponding OC clinical data as well as raw counts of gene expression for tumor-associated samples were downloaded through the TCGA biolinks package.